SCHEMBL7677151

SCHEMBL7677151

Cc1ccc2c(c1)N(C[C@H](C)NC(=O)OC(C)(C)C)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HTR2A P28223 4/20 0.40
HTR2C P28335 4/20 0.40
HTR2B P41595 4/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
NFKB1 P19838 1/20 0.40
HIF1A Q16665 1/20 0.40
NR1I3 Q14994 3/20 0.40
LMNA P02545 1/20 0.39
PMP22 Q01453 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GFER P55789 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSK P43235 1/20 0.39
SCN9A Q15858 4/20 0.38
CTSS P25774 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7677157 1.00 HDAC1 (0.43) HDAC1HDAC6HTR2AHTR2CHTR2B
SCHEMBL7673597 0.88 HTR2A (0.56) HDAC1HDAC6HTR2AHTR2CHTR2B
SCHEMBL7674588 0.88 HTR2A (0.56) HDAC1HDAC6HTR2AHTR2CHTR2B
SCHEMBL7673592 0.88 HTR2A (0.56) HDAC1HDAC6HTR2AHTR2CHTR2B
SCHEMBL7674593 0.88 HTR2A (0.56) HDAC1HDAC6HTR2AHTR2CHTR2B
SCHEMBL7677943 0.85 CTSK (0.45) HDAC1HDAC6NR1I3CTSLCTSB
SCHEMBL7677937 0.85 CTSK (0.45) HDAC1HDAC6NR1I3CTSLCTSB
SCHEMBL1435950 0.83 LMNA (0.40) HDAC1HDAC6NR1I3LMNACTSL
SCHEMBL7677907 0.82 CTSS (0.42) LMNACTSLCTSKCTSSMEN1
SCHEMBL7677911 0.82 CTSS (0.42) LMNACTSLCTSKCTSSMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380238-B1 FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-30 US disclosed
EP-1109784-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2001-06-27 EP disclosed
WO-2000012475-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO disclosed